By Karen Roman
Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively.
The additions come as Inventiva prepares for potential commercialization from the Phase 3 trial of its MASH therapeutic, expected in the fourth quarter of 2026, it stated.
“We believe we are well-positioned to guide Inventiva through its next phase with confidence, discipline, and speed, from pivotal data readouts to potential regulatory submissions and commercialization,” said Andrew Obenshain, Inventiva’s CEO.
READ MORE
Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment
Never Miss our Weekly Highlights HERE
